Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 7 institutions in 3 countries.
Karol WtorekDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.ORCID 0000-0002-3567-6962
Alessia GhidiniDepartment of Chemistry "G. Ciamician", University of Bologna, Via Selmi 2, 40126 Bologna, Italy.ORCID 0000-0003-1063-7067
Luca GentilucciDepartment of Chemistry "G. Ciamician", University of Bologna, Via Selmi 2, 40126 Bologna, Italy.ORCID 0000-0001-9134-3161
Anna Adamska-BartłomiejczykDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Justyna Piekielna-CiesielskaDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Chiara RuzzaDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0003-1360-202X
Chiara SturaroDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-2708-9223
Girolamo CalòDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo Meneghetti 2, 35131 Padova, Italy.
Stefano PierettiIstituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.ORCID 0000-0001-5926-6194
Alicja KluczykFaculty of Chemistry, University of Wroclaw, 50-383 Wroclaw, Poland.ORCID 0000-0003-2943-2782
John McDonaldDepartment of Cardiovascular Sciences, University of Leicester, Anaesthesia, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
David G LambertDepartment of Cardiovascular Sciences, University of Leicester, Anaesthesia, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester LE2 7LX, UK.ORCID 0000-0003-4769-8090
Anna JaneckaDepartment of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
Medical University of Lodz · PLUniversity of Bologna · ITUniversity of Ferrara · ITUniversity of Leicester · GBIstituto Superiore di Sanità · ITUniversity of Padua · ITUniversity of Wrocław · PL
Funding
Medical University of Lodz 503/1-156-02/503-11-001-19-00
6 · The paper itself
Abstract
Recently, mixed opioid/NOP agonists came to the spotlight for their favorable functional profiles and promising outcomes in clinical trials as novel analgesics. This study reports on two novel chimeric peptides incorporating the fragment Tyr-c[D-Lys-Phe-Phe]Asp-NH
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors. · full record | OpenQuestion